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Homeodomain-interacting protein kinase 2 (HIPK2) is a multitalented protein that exploits its kinase activity to
modulate key molecular pathways in cancer to restrain tumor growth and induce response to therapies. HIPK2
phosphorylates oncosuppressor p53 for apoptotic activation. In addition, also p53-independent apoptotic pathways
are regulated by HIPK2 and can be exploited for anticancer purpose too. Therefore, HIPK2 activity is considered a
central switch in targeting tumor cells toward apoptosis upon genotoxic damage and the preservation and/or
restoration of HIPK2 function is crucial for an efficient tumor response to therapies. As a proof of principle,
HIPK2 knockdown impairs p53 function, induces chemoresistance, angiogenesis, and tumor growth in vivo, on the
contrary, HIPK2 overexpression activates apoptotic pathways, counteracts hypoxia, inhibits angiogenesis, and
induces chemosensitivity both in p53-dependent and -independent ways. The role of HIPK2 in restraining tumor
development was also confirmed by studies with HIPK2 knockout mice. Recent findings demonstrated that HIPK2
inhibitions do exist in tumors and depend by several mechanisms including HIPK2 cytoplasmic localization,
protein degradation, and loss of heterozygosity (LOH), recapitulating the biological outcome obtained by RNA
interference studies in tumor cells, such as p53 inactivation, resistance to therapies, apoptosis inhibition, and tumor
progression. These findings may lead to new diagnostic and therapeutic approaches for treating cancer patients.
This review will focus on the last updates about HIPK2 contribution in tumorigenesis and cancer treatment.
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An outstanding problem in cancer therapy is the battle
against treatment-resistant disease. Several genetic and
epigenetic conditions as well as microenvironment mod-
ifications, contribute to tumor resistance to therapies,
including p53 inactivation, induction of hypoxia, im-
munosuppression, and DNA repair [1]. One of the most
promising molecules that might be exploited in antican-
cer therapy is homeodomain-interacting protein kinase 2
(HIPK2). HIPK2 has been discovered more than 10 years
ago as a nuclear serine/threonine kinase that acts as core-
pressor for transcription factors [2]. Since then, HIPK2
has been shown to regulate gene expression, during DNA* Correspondence: gdorazi@unich.it; soddu@ifo.it
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reproduction in any medium, provided the ordamage response and development, by phosphorylating a
ever growing number of transcription factors and by
recruiting corepressor components involved in gene tran-
scription, as summarized in several reviewss [3,4]. HIPK2
function is important in anticancer therapy because it
induces tumor cell apoptosis, an outcome obtained by ac-
tivating various downstream signaling pathways [5], most
prominently oncosuppressor p53 [6]. HIPK2 may induce
apoptosis also by modulating molecules independently by
p53, such as through phosphorylation-dependent degrad-
ation of anti-apoptotic transcriptional corepressor CtBP
[7], underlying its role as regulator of several different
molecules.
The p53 tumor suppressor is a zinc-protein that is acti-
vated in response to DNA damage [8]. The function of
p53 as a tumor suppressor is linked to its activity as tran-
scription factor through posttranslational modifications
that allow the protein to bind DNA and induce target
genes (encoding both proteins and microRNA) involvedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its crucial role as “guardian of the genome”, tumors press
to inactivate p53 at different tumor stages through sev-
eral mechanisms including gene mutations, protein in-
activation, or inactivation of p53 regulatory proteins [10].
Impairment of p53 function has a crucial role in tumor
evolution by allowing evasion from p53-dependent
responses. Therefore, restoration of p53 activity in tumor
cells is a valuable intervention for tumor regression [11].
Recent studies from our groups and others’ have shed
new lights on various aspects of p53 regulation by HIPK2
and have served to both increase the complexity of the
p53 regulatory pathways, including p53 inhibitors (i.e.,
MDM2) and p53-family members (i.e., ΔNp63α) but also
to underline a role for HIPK2 as tumor suppressor itself
for anticancer therapy, that we will discuss here. Thus,
HIPK2 inactivation unlashes signaling pathways that lead
to p53 dysfunction, chemoresistance, angiogenesis and
tumor growth [12,13]. For these reasons, HIPK2 is a
promising biomarker and a target for tumor therapy.
Understanding the molecular mechanisms underlying
HIPK2 activation and inactivation will therefore give
more insight into its role in tumor development and
regression.
HIPK2 activates p53 apoptotic function in response to
genotoxic stress
HIPK2 can be activated by several types of genotoxic
damage, including ultraviolet radiation (UV), ionizing ra-
diation (IR), and antitumor drugs such as cisplatin
(CDDP), adriamycin (ADR) and roscovitin [6,14-16].
One of the main molecules activated by HIPK2 is the
p53 oncosuppressor. HIPK2 phosphorylates p53 at serine
46 (Ser46) [6] and allows recruitment of histone acetylase
(HAT) p300 for efficient p53 acetylation at lysine 382
(Lys382) [17]. These p53 posttranslational modifications
specifically induce p53-dependent pro-apoptotic gene
transcription (i.e., p53AIP1, Noxa, Puma, Bax, Killer DR5)
while p53 regulatory genes such as MDM2 or cell-cycle
arrest related p21 are not induced [12,18]. Interestingly,
p53 activation induces caspase-6 which is responsible for
caspase-mediated HIPK2 cleavage at positions 916 and
977 [19]. This C-terminus truncated HIPK2 results in a
hyperactive kinase which potentiates p53Ser46 phosphor-
ylation and activation of apoptosis and eventually is
degraded. Thus, caspase-resistant HIPK2 mutants induce
apoptosis less efficiently than wild-type [19]. These find-
ings suggest a tight regulation of HIPK2 in a p53-
dependent manner, a regulatory loop similar to the
elimination of ERK2 kinase by a p53-induced apoptotic
program, in order to prevent ERK-mediated cell prolif-
eration in the presence of activated p53 [20].
HIPK2 is a critical activator of p53 function in re-
sponse to drugs as substantiate by experiments of HIPK2gene silencing by small interference RNA (siRNA).
HIPK2 knockdown impairs p53 pro-apoptotic gene tran-
scription in response to drugs and predisposes to che-
moresistance [14] and increased tumor growth in vivo
[21]. HIPK2 knockdown contributes to p53 inactivation
by different means other than by direct impairment of
p53Ser46 phosphorylation. cDNA microarray of colon
cancer cells with chronic depletion of HIPK2 function
by siRNA [22], showed upregulation of two novel targets
of HIPK2 corepressor function that are involved in p53
deregulation, that is, Nox1 and MT2A. Thus, HIPK2 has
been shown to repress Nox1 promoter activity [23].
Nox1 is a homolog of the catalytic subunit of the
superoxide-generating NADPH-oxidase that is often
overexpressed in tumors and is involved in tumor pro-
gression and angiogenesis [24]. HIPK2 knockdown
induces Nox1 upregulation and Nox1 overexpression
impairs p53 apoptotic transcriptional activity by indu-
cing p53Lys382 deacetylation [23].
Interestingly, chronic HIPK2 depletion leads to p53
protein misfolding, as assessed by immunoprecipitation
studies with conformation-specific p53 antibodies, that
impairs p53/DNA binding and p53 transcriptional activ-
ity [22]. This p53 misfolding, in colon and breast cancer
cells, could be, at least in part, ascribed to metallothio-
nein 2A (MT2A) upregulation upon HIPK2 depletion
[25]. Thus, MT2A depletion by siRNA, restores wtp53
native conformation and p53 function in response to
drugs, in HIPK2 knockdown cells [25]. Metallothionein
is a family of at least 10 conserved isoforms of metal-
binding cysteine-rich proteins with a potential role in
homeostasis of essential metals [26]. MTs upregulation
has been found in several human tumors including
breast, colon, liver, and lung, and supports a role for
MTs in acquired drug resistance [27]. In most cell types,
zinc is often sequestered through binding to MTs, keep-
ing free zinc concentrations fairly low that could account
for lack of function in a typical zinc-sensitive protein,
such as p53 [28]. Indeed, zinc supplementation to
HIPK2-depleted cells restores p53 native conformation
and transcriptional activity in response to drugs, as well
as increases in vivo tumor regression in combination
with anticancer drug adryamicin (ADR) in a xenograft
colon cancer cell model [22]. The finding of p53 mis-
folding upon HIPK2 depletion was corroborated by
in vivo studies in mice with the transgenic MMTV-neu
spontaneous breast cancer model that revealed low
HIPK2 gene expression in the tumor tissue compared to
normal tissue, that correlated with misfolded p53 [29].
Zinc treatment in combination with anticancer drug
adryamicin remarkably reduced spontaneous tumor
growth compared to drug treatment alone, restoring
wild-type p53 (wtp53) conformation and p53 apoptotic
transcriptional activity [29].
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in response to DNA damage is the LIM (Lin-11. Isl-I and
Mec3) domain protein Zyxin, a regulator of the actin
skeleton and focal adhesions, that stabilizes HIPK2 by
inhibiting Siah-1-mediated HIPK2 degradation [30]. De-
pletion of Zyxin, therefore, inhibits HIPK2 stabilization
and DNA damage-induced p53Ser46 phosphorylation
and apoptosis. Another molecule that fine-tunes the p53
activation threshold in response to differing severities of
genotoxic stress is Axin that allows distinct complexes
formation of p53 with molecules Pirh2, Tip60 and HIPK2
[31]. Under sublethal DNA damage, Pirh2 abrogates
Axin-induced p53Ser46 phosphorylation by competing
with HIPK2 for binding to Axin. Under lethal DNA
damage Tip abrogates Pirh2-Axin binding forming an
Axin-Tip60-HIPK2-p53 complex that allows p53 apop-
totic activation [31].
HIPK2 regulates molecules involved in p53-dependent
and -independent apoptosis in response to genotoxic
damage
HIPK2 promotes apoptosis by modulating factors, dir-
ectly or indirectly related to p53, such as the antiapopto-
tic transcriptional corepressor CtBP [7], the p53
inhibitor MDM2 [32] and ΔNp63α [33]. HIPK2 partici-
pates in a pathway of UV-triggered CtBP clearance that
results in cell death. HIPK2 phosphorylates CtBP at Ser-
422 that induces protein degradation. Thus, HIPK2
knock-down inhibits UV-induced CtBP-Ser-422 phos-
phorylation and degradation in p53-null H1299 lung
cancer cells, confirming HIPK2 role in apoptosis also in
cells lacking p53 [7,34]. MDM2 is the main p53 negative
regulator, it is an oncogene often upregulated in tumors
and for these reasons many studies are devoted to the
development of small molecules to inhibit MDM2 and
restore p53 activity [11,35]. HIPK2, by phosphorylating
MDM2 for proteasomal degradation [36], may overcome
the MDM2-induced p53 inactivation and restore p53
apoptotic activity [32]. On the other hand, an intriguing
regulatory circuitry between MDM2 and HIPK2/p53 axis
revealed that sublethal DNA damage leads to HIPK2 in-
hibition by a protein degradation mechanism involving
p53-induced MDM2 activity [37]. These findings high-
light a role for MDM2 to fine-tune the p53-mediated
biological outcomes (that is, cell cycle arrest vs apop-
tosis) according to cell requirement. However, this also
explains the p53 inactivation in tumors overexpressing
MDM2, nonetheless the presence of wtp53. In this latter
case, the use of the small molecule RITA (reactivation of
p53 and induction of tumor cell apoptosis) that inhibits
MDM2/p53 interaction and induces expression of p53
target genes and massive apoptosis in various tumor
cells lines [35], can be useful to counteract HIPK2 deg-
radation and to reactivate p53 apoptotic function [38].Interestingly, also zinc ions treatment has been shown to
relapse the MDM2-induced HIPK2 downregulation, by
counteracting the MDM2 E3 ubiquitin ligase activity fi-
nally reactivating the HIPK2-induced p53Ser46 phos-
phorylation and apoptotic activity [39], although the
molecular mechanism needs to be elucidated.
HIPK2 depletion has been shown to induce cancer cell
resistance to different anticancer drugs even in p53-null
cells, suggesting the involvement of additional HIPK2
targets other than p53. In particular, it has been found
that HIPK2 phosphorylates and promotes proteasomal
degradation of ΔNp63α, a prosurvival dominant negative
(DN) isoform of the p53 family member p63. HIPK2
phosphorylates ΔNp63α at the T397 residue, thus, the
nonphosphorylatable ΔNp63α-T397A mutant is not
degraded in spite of either HIPK2 overexpression or
ADR treatment. These findings underline ΔNp63α as a
novel HIPK2 target in response to genotoxic drugs [33].
These data indicate that HIPK2 has a double commit-
ment, working as activator for proapoptotic factors (i.e.,
p53) on one hand and inhibitor for antiapoptotic factors
(i.e., CtBP, MDM2, ΔNp63α, HIF-1α) on the other hand.
On the opposite side, these considerations would allow
to suppose that tumor-associated inhibition of HIPK2
activity might strongly contribute to chemoresistance
and tumor progression, in addition to other better-
characterized events, such as p53 mutation/inactivation
and MDM2 or ΔNp63α overexpression.
Mechanisms of HIPK2 inhibition and its impact on both
p53 function and tumor progression
Several proteins have been shown to target the HIPK2/
p53 axis and therefore to inhibit stress- or drug-induced
apoptosis to clear cancer. Recent studies demonstrated
that High-mobility group A1 (HMGA1) proteins interact
with p53 and inhibit its apoptotic activity [40]. Interest-
ingly, HMGA1 overexpression is responsible for HIPK2
cytoplasmic sequestration and the subsequent inhibition
of HIPK2/p53 interaction and apoptosis activation [41].
HMGA1 is frequently overexpressed in tumors and cor-
relates with low apoptotic index in wild-type p53 breast
cancer tissues [41]. Thus, immunostaining of breast
ductal carcinomas with low HMGA1 expression and
with high apoptotic index (not shown) results in HIPK2
nuclear localization (Figure 1A). On the other hand,
breast ductal carcinomas with high HMGA1 expression
and with low apoptotic index (not shown) show HIPK2
cytoplasmic localization (Figure 1B), meaning likely
HIPK2 inactivation [41]. Similar HIPK2 cytoplasmic
localization was found in breast cancer tissues with over-
expression of integrin alpha(6)beta(4), which is also
involved in impairment of p53 apoptotic activity [42], in-
dicating that HIPK2 cytoplasmic relocalization may be a
negative marker for p53 function.
Figure 1 HIPK2 immunostaining in breast cancer. Streptavidin-biotin immunoperoxidase staining of invasive breast ductal carcinomas
displaying (A) nuclear HIPK2 localization, and (B) cytoplasmic HIPK2 localization. Magnification 40X. (kindly provided by Dr. Marcella Mottolese,
IFO-IRE, Rome, Italy).
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Galectin-3 (Gal-3), a β-galactoside-specific lectin with
anti-apoptotic activity, involved in tumorigenesis and re-
sistance to chemotherapeutic drugs [43]. Intriguingly,
though, Gal-3 is highly expressed in well-differentiated
thyroid carcinomas (WDTCs) nonetheless the presence
of wild-type p53 supposed to negatively regulate Gal-3.
This paradoxical behavior may be explained by hypothe-
sizing that in WDTC wtp53 protein is inactive. Thus,
Real-Time PCR on total RNA extracted from frozen thy-
roid tissues samples as well as immuonohistochemistry
analyses revealed that HIPK2 is indeed downregulated in
WDTCs [44]. In particular, genetic loss at HIPK2 locus
7q32-34 was found by loss of heterozigosity (LOH) ana-
lysis in thyroid cancer cells stained with Gal-3 and
retrieved by Laser Capture Microdissection (LCM) [44].
This study demonstrates that the loss of HIPK2 expres-
sion in WDTC may be responsible for lack of p53 activa-
tion, thus explaining the paradoxical co-expression of
wild-type p53 with overexpressed Gal-3. Of interest,
HIPK2 LOH was also observed in mice. In particular, a
screening for genetic alterations in radiation-induced
thymic lymphomas demonstrated that Hipk2 is a hap-
loinsufficient tumor suppressor gene in vivo, showing
loss of one Hipk2 allele in 30 % of the tumors and
increased susceptibility of Hipk2+/− mice to radiation-
induced thymic lymphoma [45]. This study provides
compelling evidence that Hipk2 functions as major
tumor suppressor in response to ionising radiation
in vivo. Interestingly, this function appears to be in part
independent of p53.
An intact p53 is crucial for chemotherapy-induced
apoptosis in MYCN-overexpressing neuroblastoma cells.
Thus, MYCN sensitizes neuroblastoma cells to apoptosis
by upregulation of the HIPK2/p53Ser46 pathway via
ATM-dependent DNA damage response (DDR) that acti-
vates HIPK2 [46]. HIPK2 is largely expressed in human
primary MYCN amplification (MNA) neuroblastomatissues and its expression is induced by MYCN, whose
inactivation inhibits HIPK2 and impairs p53Ser46 phos-
phorylation and apoptosis [46].
An abnormal HIPK2 function was recently associated
to skin carcinogenesis. This study investigated a link be-
tween oncogene E6 of genital high-risk human papillo-
mavirus (HPV) and HIPK2. The authors found that only
E6 of beta2PV types (HPV23 and HPV38), but not
beta1PV types (HPV8 and HPV20), cutaneous gam-
maPV (HPV4) or genital HPV16, physically interacts
with HIPK2, inhibiting HIPK2-mediated p53Set46 phos-
phorylation by enforcing dissociation of the HIPK2/p53
complex [47]. This is relevant because HPV infection of
keratinocytes prevents UV-activated cell death and thus
may contribute to skin carcinogenesis, suggesting a pos-
sible mechanism that is inhibition of the HIPK2/p53
function. This finding highlights the role of HIPK2 as
tumor suppressor that is in line with the outcome of
genetic HIPK2 deletion in mice where Hipk2−/− and
Hipk2+/− mice are tumor prone and undergo skin car-
cinogenesis by the two stage carcinogenesis protocol,
showing that HIPK2 acts as a tumor suppressor in the
skin [48]. The molecular mechanism was identified in
increased Wnt/β-catenin-mediated cyclin D1 target gene
expression, which is involved in cell proliferation. Thus,
HIPK2 forms a protein complex with β-catenin and
recruits the corepressor CtBP for cyclin D1 repression
[48]. Subsequent studies demonstrated that HIPK2
phosphorylates β-catenin for proteasomal degradation
[49], thus interfering with the transcription of several β-
catenin target genes, including vascular endothelial
growth factor (VEGF) involved in tumor angiogenesis
and tumor growth [50].
Few mutation were also found in human acute mye-
loid leukemias (AMLs), which lead to aberrant HIPK2
nuclear distribution with impairment of p53 apoptotic
transcriptional activity [51], confirming the role of
HIPK2 in p53 activation to counteract tumor growth.
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incidence of HIPK2 mutations in tumors.
A physiological condition that inhibits HIPK2 func-
tions in solid tumor is hypoxia [52], a hallmark of tumor
progression and failure of tumor therapies. Hypoxia acti-
vates the RING family ligase seven in absentia homolog-
2 (Siah-2) that induces HIPK2 proteasomal degradation
[52]. The presence of hypoxia renders tumor cells resist-
ant to conventional chemo- and radiotherapy selecting a
more malignant and invasive phenotype and plays a
negative role in patient prognosis [53]. The key mediator
in response to decreased oxygen availability is the tran-
scription factor hypoxia-inducible factor-1 (HIF-1) that
induces genes involved in angiogenesis, chemoresistance,
glucose metabolism, and invasion. HIF-1 consists of the
constitutively expressed HIF-1β subunit and the HIF-1α
subunit, whose stability is stimulated by low oxygen or
genetic alterations [53]. In this regard, it has been shown
that HIPK2 represses HIF-1α gene transcription [54]
counteracting the hypoxic phenotype and restoring
tumor cell chemosensitivity in tumor cells irrespective of
the TP53 gene status [55]. Restoration of tumor cell che-
mosensitivity was also reported in another study show-
ing that exogenous HIPK2 overexpression was able to
circumvent inhibition of apoptosis in cisplatin-resistant
ovarian cancer cells [56] although the molecular mech-
anism is still elusive. HIF-1α overexpression has been
shown to antagonize p53-mediated apoptosis [57] also
because HIF-1α may induce HIPK2 proteasomal degrad-
ation therefore inhibiting p53Ser46 phosphorylation
[58]. This novel regulatory circuitry between HIF-1α,
HIPK2 and p53 molecules gives a mechanistic explan-
ation of the p53 apoptotic inhibition in response to drugFigure 2 Schematic representation of HIPK2 activation/inactivation. H
mechanisms of HIPK2 inhibition are: cytoplasmic localization, hypoxia, gene
inhibits the oncogenic Wnt/β-catenin and HIF-1 pathways. HIPK2 activates
and ΔNp63α proteins.under hypoxia in those tumors that retain a nonfunc-
tional wild-type p53 [58]. Interestingly, HIF-1α may be
targeted by zinc ions that induce HIF-1α proteasomal
degradation [59], opening a way to reactivate the
hypoxia-inhibited HIPK2/p53 pathway that could be
exploited in vivo. This finding was corroborated by
cDNA microarray studies in hypoxia-treated cancer cells,
showing that zinc ions indeed reverse the hypoxia-
induced gene transcription [60]. In summary, several dif-
ferent mechanisms that inhibit HIPK2 in tumors were
identified, leading mainly to impairment of p53 response
to drugs but also to induction of oncogenic pathways im-
portant in tumor progression, angiogenesis and chemore-
sistance such as Wnt/β-catenin and HIF-1 (Figure 2).
During hypoxia, HIPK2 can be reactivated by zinc treat-
ment that becomes a valuable tool to be used in combin-
ation with anticancer drugs to restore the HIPK2/p53
pathway.
A novel role of HIPK2 in controlling cytokinesis and
preventing tetraploidization
Recently, an unexpected subcellular localization and bio-
logical function of HIPK2 in cytokinesis was identified
[61]. In cytokinesis daughter cells separate by constriction
of the cytoplasmic intercellular bridge between the two
re-forming nuclei at the final step of cell division. Failure
of cytokinesis may generate tetraploid cells. With the ex-
ception of rare cell types, such as hepatocytes, which can
exist as stable tetraploids, tetraploid cells have chromo-
some unstable state that can lead to aneuploidy and ul-
timately to tumorigenic transformation [62]. Alike several
abscission’s regulatory and effector components, HIPK2
and its novel target, the histone H2B, was shown toIPK2 can be activated by: drugs, IR, UV, roscovitin. The so far known
mutation, LOH, and HPV23 E6 or HMGA1 overexpression. HIPK2
p53 for apoptotic function and inhibits the antiapoptotic CtBP, MDM2
Figure 4 HIPK2 knockout induces bi- and multi-nucleation.
Mouse embryo fibroblasts (MEFs) were obtained by wild-type (Hipk2
+/+) and knockout (Hipk2-/-) mice. Cell nuclei were stained with
Hoechst. Arrows indicate bi- and- multi-nucleated cells. BF: bright
field. Bar is 10 micron.
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during cytokinesis. HIPK2 binds directly histone H2B and
phosphorylates it at serine residue 14 (Ser14). Despite the
apoptotic functions of both HIPK2 and the S14 phos-
phorylated form of H2B (H2B-S14P), the two proteins co-
localize at the midbody (Figure 3), independently of the
presence of chromatin in the cleavage plane, DNA dam-
age, and/or apoptosis. HIPK2-depletion by targeted gene
disruption or siRNA interference results in loss of H2B-
S14P at the midbody, impairs abscission, the final step of
cytokinesis, and induces accumulation of cytokinesis-
dependent aberrations, including tetra- and poly-
ploidization (Figure 4). Remarkably, the expression of a
phospho-mimetic H2B-S14D mutant can rescue these
cytokinesis defects, showing that HIPK2-mediated H2B-
S14 phosphorylation is required for a faithful cytokinesis
[61]. This study suggests that HIPK2 may function as
tumor suppressor also by preventing tetraploid cell for-
mation and may have important implications to compre-
hend the mechanisms of safeguard from ploidy in which
the p53 tumor suppressor is known to play important
roles. Indeed, because of the key role of HIPK2 in p53
pro-apoptotic activation, HIPK2 inactivation may at once
generate tetraploid cells and suppress their safety control.
This latter statement is in agreement with a previous
study showing that HIPK2 knockdown strongly abolished
the tumor cell capacity to repair damaged DNA, at least
in part through impairment of p53-function, suggesting
that HIPK2 inhibition might increase genomic instability
and thereby favor tumor progression [63]. In addition, the
HIPK2-induced H2B activation reveals an unpredicted
function of the extra-chromosomal activity of the H2B
core histone, whose requirement for faithful cytokinesis
can become a target for anti-cancer drugs. In future stud-
ies it would be interesting to evaluate in tumors the asso-
ciation between loss of HIPK2 function, H2B-S14
phosphorylation at the midbody and tetraploidy.
Conclusion
In conclusion, the above summarized findings demon-
strate how HIPK2 is important in inducing the apoptoticFigure 3 HIPK2 and H2B-Ser14P co-localization at midbody. HeLa cells
immunostaining was performed with anti-Flag (green) and with anti phosp
midbody. Merge shows HIPK2 and H2B-Ser14P co-localization at midbody.tumor response to genotoxic damage, and how is deeply
involved in p53 regulation through different mechanisms
including protein phosphorylation, acetylation, and pro-
tein conformation. HIPK2 may also indirectly affect p53
apoptotic function by modulating proteins involved in
p53 deregulation such as Nox1, MT2A, MDM2, that are
often upregulated in tumors and that account for tumor
progression and chemoresistance. However, HIPK2 may
induce apoptosis even in p53-null cells, downregulating
for instance molecules such as antiapoptotic CtBP and
ΔNp63α. These findings underscore how HIPK2 might
affect several signaling pathways, including the onco-
genic Wnt/β-catenin or HIF-1 pathways, involved inwere transfected with Flag-HIPK2 expression vector and
ho-Histone2B-Ser14 (H2B-Ser14P, red) antibodies. White arrows show
Bar is 10 micron.
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They also underline the need to maintain an intact
HIPK2 function. Among the mechanisms of HIPK2 in-
hibition it is lately becoming clear that hypoxia might
negatively affect HIPK2 function and thereby indirectly
also p53 oncosuppressor function. HIPK2 may undergo
to some mutations, and another intriguing mechanism
of HIPK2 inhibition is the reported LOH in well differ-
entiated thyroid carcinomas and in mice. Moreover, the
just discovered role of HIPK2 in cytokinesis implies its
control on chromosomal instability which allows tumori-
genesis. Therefore, these findings, by demonstrating the
contributions of HIPK2 signaling to tumor regression
and response to therapies, propose HIPK2 as potential
diagnostic marker and a therapeutic target. What does
the future hold for this promising tumor suppressor pro-
tein? Other than unveiling novel roles for HIPK2 in
anticancer mechanisms, one intriguing area will be to
discover selective compounds for HIPK2 (re)activation,
for anticancer therapeutic purpose.
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